• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Invariant NKT Cell Ligands for Prostate Cancer Vaccines
【24h】

Invariant NKT Cell Ligands for Prostate Cancer Vaccines

机译：用于前列腺癌疫苗的不变NKT细胞配体

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Invariant natural killer T cells (iNKT cells), through their ability to mature dendritic cells (DCs) and provide help for CD4 and CD8 T cell responses, can play a major role in regulation of the cellular adaptive immune response. Our major objective in this proposal is to identify an optimal agent and method of delivery for iNKT cell activation and enhancement of cytolytic T cell responses against prostate/PCa associated antigens. Our findings with respect to peptide based vaccines are not yet conclusive due largely to modest and inconsistent responses to peptides. It is well established that peptides (alone or pulsed onto DCs) are not optimal immunogens, and it is not yet clear whether or to what extent we can boost their efficacy using iNKT cell ligands. Over the next year we will assess some alternate approaches including the use of longer or modified peptides and other modes of administration, as the use of peptide or peptide pools still offers substantial advantages with respect to human clinical trials. In contrast to peptides, the data indicate that iNKT cell ligands can enhance responses to cellular vaccines. Therefore, in parallel with the peptide efforts, we will use this approach to assess alternative iNKT cell ligands and begin to assess efficacy in tumor bearing mice.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号